Tuberculosis, caused by Mycobacterium tuberculosis , is one of the three major deadly diseases. The  improvement of hygiene condition and the  marketing of the current first line anti-tuberculosis drug�isoniazid,  pyrazinamide, ethambutol and rifampin� in the 1950-1960s have signficanlty prevented and treated  or cured the disease. However, the outbreak of multi-drug-resistant tuberculosis (MDR-TB)  in the  1980s and the emergence of extensive-drug-resistant   tuberculosis (XDR-TB) in 2006 call for new chemotherapies interacting with new drug targets or multiple drug targets. SQ-109, developed by Sequella Inc., is a promising TB drug candidate with activity against MDR-TB strains and XDR-TB strains that is in clinical trials. But the mechanism of action of SQ-109 is somewhat unclear. We synthesized a series of SQ-109  analogs to explore the mechanism of action in a variety organisms.

Mechanism of action of SQ-109 analogs in a variety of organisms

246th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.